Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Andexxa (andexanet alfa), the only specific anti-Xa reversal agent, has been withdrawn from the US market on December 22, 2025.
It was marketed for the reversal of Rivaroxaban and Apixaban.
The theory was great, but it was very expensive and had a higher thrombotic risk than when PCC was used for reversal.
Below is the announcement on the FDA website.
As far as I know, it is still being sold and used in Europe, but I can not see this continuing.
There is nothing on the EMA website.
Also, rather surprisingly, there is no mention of this on the AstraZeneca US or UK websites about this.
Do their medical communication teams not work in the second part of December?”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026